Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 5;7(4):e863.
doi: 10.1097/HS9.0000000000000863. eCollection 2023 Apr.

Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment

Wendy B C Stevens  1 , G Tjitske Los-de Vries  2 , Carole Langois-Jacques  3   4   5 , Andrew J Clear  6 , Phylicia Stathi  2 , Birgitta Sander  7 , Andreas Rosenwald  8   9 , Maria Calaminici  6 , Eva Hoster  10   11 , Wolfgang Hiddemann  11 , Philippe Gaulard  12 , Gilles Salles  13 , Wolfram Klapper  14 , Luc Xerri  15 , Catherine Burton  16 , Reuben M Tooze  17 , Alexandra G Smith  18 , Christian Buske  19 , David W Scott  20 , Yasodha Natkunam  21   22 , Ranjana Advani  22   23 , Laurie H Sehn  20 , John Raemaekers  1 , John Gribben  6 , Sandra Lockmer  24 , Eva Kimby  24 , Marie José Kersten  25 , Delphine Maucort-Boulch  3   4   5 , Bauke Ylstra  2 , Erik van Dijk  2 , Daphne de Jong  2
Affiliations

Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment

Wendy B C Stevens et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Microenvironment, mutations, translocations, and copy number landscape of Watch-and-Wait vs Immediate Treatment patients with follicular lymphoma. (A) For W&W (n = 60) and IT (n = 99) CD4, CD8, CD3, FOXP3, and PD1 are computer assisted scored and the percentage of positive nucleated cells of all nucleated cells are depicted as boxplots. CD163 and CD68 are computer assisted scored and the percentage of positive area of the total cell area scored are plotted in the boxplots. None of the markers show a significant difference. (B) Frequency of top 25 alterations including BLC2 and BLC6 translocations and mutated genes, W&W (n = 44) is depicted in yellow and IT (n = 46) in blue, no significant differences were found (P < 0.05, Fisher exact test and FDR using Benjamini&Hochberg method). (C) Comparison plots for CNAs between W&W (filled n = 44) and IT (line n = 46) depicted are percentages of the number of cases with gains (positive value red) and losses (negative value blue), sorted for chromosome position (x-axis). (D) P values (orange) calculated with a 2-sided rank sum test with 10,000 permutations and FDR (striped blue segments) of the difference in CNAs, the horizontal red dotted lines show the significance thresholds P value <0.05, and the FDR in blue <0.1. No significant differences were found. (E) Total number of nonsynonymous and splice-site mutations per patient are depicted in boxplots. With a median of 9 nonsynonymous and splice-site mutations (mean 9.52, range 2–22) in the W&W cohort (yellow) vs a median of 12.5 nonsynonymous and splice-site mutations (mean 13.07, range 4–32) in the IT cohort (blue), this is a significant difference, Wilcoxon test P value = 0.003. (F) Copy number load is depicted in boxplots. For the W&W cohort (yellow), a median of 7.79% (mean 13.22%) vs a median of 12.11% (mean 19.18%) for the IT cohort (blue), this is a significant difference, Wilcoxon test P value = 0.045. CNAs = copy number aberrations; FDR = false discover rates; IT = immediate treatment; W&W = Watch-and-Wait.
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390. - PMC - PubMed
    1. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265. - PubMed
    1. Nastoupil LJ, Sinha R, Byrtek M, et al. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. Br J Haematol. 2016;172:724–734. - PubMed
    1. Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15:424–435. - PubMed
    1. Yuda S, Maruyama D, Maeshima AM, et al. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era. Ann Hematol. 2016;95:2017–2022. - PMC - PubMed